HTFL

Heartflow, Inc. (HTFL) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Heartflow, Inc. is a commercial-stage medical technology company utilizing AI and computational fluid dynamics to diagnose coronary artery disease (CAD) via its Heartflow Platform. The quarter was defined by the company's transition to public status, completing its Initial Public Offering (IPO) on August 11, 2025, and a reverse stock split effective July 31, 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 41% year-over-year in Q3 2025, driven by a 48% increase in revenue case volume. This was partially offset by a lower average sales price due to a higher mix of clinic/office-based accounts and increased volume rebates.
• Operating Expenses: Total operating expenses rose 27% to $50.5 million. R&D expenses increased 46% due to headcount growth and clinical trial costs. SG&A expenses increased 19% driven by personnel costs and public company compliance expenses.
• Non-Operating Items: The Net Loss widened significantly due to non-cash charges, including a $32.1 million loss on the change in fair value of common stock warrant liability and a $6.4 million loss on the extinguishment of debt.
• Liquidity Transformation: Cash and cash equivalents surged from $51.4 million (Dec 31, 2024) to $291.2 million (Sept 30, 2025) following the IPO, which generated approximately $332.3 million in net proceeds.
• Debt Elimination: The company repaid its $138.1 million Term Loan in full in August 2025 and converted $98.3 million of 2025 Convertible Notes into common stock upon the IPO closing.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue incurring losses as it scales operations and invests in R&D. The company believes its current cash position is sufficient to fund operations for at least the next 12 months.
• Product Strategy: Heartflow FFR CT Analysis remains the primary revenue driver (98% of total revenue). The company is expanding commercialization of Heartflow Plaque Analysis and expects to launch Heartflow PCI Planner in 2026.
• Regulatory & Legal Risks:
  • DOJ Investigation: In October 2025, the company received Civil Investigative Demands (CID) from the U.S. Department of Justice regarding the Anti-Kickback Statute and Civil False Claims Act. The outcome is uncertain and could materially impact the business.
  • Reimbursement: The company faces potential reimbursement rate reductions, including a proposed 15% reduction in Medicare rates for 2026 under the OPPS rule.
• Subsequent Events: In October 2025, the company's lender (Hayfin) net-exercised all outstanding common stock warrants for approximately 1.65 million shares.

Investor Verification Checklist

• DOJ Investigation Status: Monitor updates on the Civil Investigative Demand regarding sales and marketing practices and potential financial impact.
• Reimbursement Rates: Verify the finalization of the 2026 Medicare OPPS rule and its impact on the 15% proposed rate reduction for FFR CT Analysis.
• Warrant Liability: Confirm the final accounting treatment and equity impact of the October 2025 warrant exercise by Hayfin.
• Plaque Analysis Adoption: Track the commercial uptake and reimbursement coverage expansion for Heartflow Plaque Analysis to assess revenue diversification.
• Operating Leverage: Assess whether gross margin improvements can offset the rising R&D and SG&A costs associated with public company operations and headcount growth.